{"prompt": "['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 41 of 128', '7 Trial design', '7.1 Overall trial design', 'This is a phase 2b, double-blind, multi-centre, randomised, 5-arm, vehicle-controlled,', 'parallel-group trial. The trial is designed to establish a dose-response signal and to investigate', 'the efficacy and safety of delgocitinib cream in the treatment of adult subjects with mild to', 'severe chronic hand eczema. The trial design is illustrated in Panel 1.', 'The trial consists of a screening period, a treatment period, and a follow-up period.', 'Screening period: between 1 and 4 weeks prior to the baseline visit (Day 1)', 'The screening period has a minimum duration of 1 week and a maximum duration of 4 weeks.', \"At the screening visit, the subjects' eligibility to enter the trial will be checked. Trial-specific\", 'measurements will be performed as described in Section 11.', 'The subjects will receive training in completion of an electronic diary (eDiary) at the', 'screening visit and will be given an electronic device to record certain patient-reported', 'outcomes (PROs). Furthermore, to complete training of the eDiary and as an opportunity to', 'fill out PROs before the treatment period, subjects will be asked to complete PROs at the', 'screening visit. Completion of the eDiary will be initiated at the latest 1 week prior to the', 'baseline visit (Day 1).', 'Treatment period: 16 weeks', \"At baseline (Day 1), subjects' eligibility to enter the trial will be confirmed and if still eligible\", \"and Investigator's Global Assessment (IGA) baseline severity and regional capping have not\", 'been reached, the subjects will be randomised to one of the following 5 treatment groups in a', '1:1:1:1:1 ratio: delgocitinib cream 1, 3, 8, or 20 mg/g or delgocitinib cream vehicle.', 'The subjects will apply the investigational medicinal product (IMP) (delgocitinib cream 1, 3,', '8, or 20 mg/g or delgocitinib cream vehicle) twice daily for 16 weeks. The first application of', 'the IMP will occur at the trial site on Day 1 when all baseline assessments have been carried', 'out. The subsequent IMP applications will be performed by the subjects at home.', 'During the 16-week treatment period, the subjects will return to the trial sites for the visits', 'scheduled at Weeks 1, 2, 4, 6, 8, 10, 12, 14, and 16. On Day 4, a member of trial site', 'personnel will call the subjects for an unsolicited questioning of AEs, and to enquire about', 'compliance with treatment and eDiary completion. The last IMP application will occur before']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 42 of 128', 'the subjects attend the visit scheduled at Week 16. Efficacy and safety assessments during the', 'treatment period will be performed as described in Section 11.', 'Follow-up period: 2 weeks', 'All randomised subjects will attend a follow-up visit approximately 2 weeks after the last IMP', 'application for assessment of safety. This visit will mark the end of trial participation for', 'subjects who have completed the entire trial. For subjects who discontinue trial treatment', 'prematurely or withdraw from the trial, please refer to Section 10.3.', '7.2 Number of subjects needed', 'This trial will be conducted at approximately 25 sites in Europe and North America. The', 'anticipated minimum number of randomised subjects per trial site is 6 and the maximum', 'number of subjects per trial site is 30.', 'Assuming a screening failure rate of 35%, approximately 385 subjects will be screened and', 'approximately 250 subjects will be randomly assigned to a treatment group in the trial', '(50 subjects in each of the 5 treatment groups: delgocitinib cream 1, 3, 8, and 20 mg/g and', 'delgocitinib cream vehicle). The statistical power considerations for this sample size are', 'described in Section 14.1.', 'The randomisation is stratified by the severity of chronic hand eczema according to IGA', '(IGA score of 2 [mild], 3 [moderate], or 4 [severe]) and region (Europe and North America).', 'A lower limit of 20% and an upper limit of 30% will be imposed on the IGA baseline severity', 'of subjects with mild and severe chronic hand eczema, respectively. Based on this capping,', 'the overall number of subjects in each severity group can range between:', 'Mild: 50 to 75 subjects.', 'Moderate: 100 to 150 subjects.', 'Severe: 50 to 75 subjects.', 'A', 'maximum of 50 subjects will be randomised in the North American region.', '7.3 End of trial definition', 'A subject is considered to have completed the trial if he/she has completed all periods (i.e.,', 'screening, treatment, and follow-up period).']\n\n###\n\n", "completion": "END"}